# Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

> **NCT02100618** · PHASE3 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **PROCEDURE:** Blood sampling

## Key facts

- **NCT ID:** NCT02100618
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to late study start, the possibility to enroll enough subjects dropped below the limit to provide scientifically acceptable data, hence study was cancelled.
- **Last updated:** 2015-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100618, "Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02100618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*